THAT WHICH IS CLAIMED IS:

1. A compound of formula (I):

$$R_1$$
 NH
 $(CH_2)_q$
 R_3
 (I)

wherein:

A is a 5- or 6-membered aromatic or heteroaromatic ring containing 0 to 4 heteroatoms selected from the group consisting of N, O, and S;

 R_1 or R_2 is of the formula (i):

$$(CH_2)_r$$
— $-A'$ — $-R_4$ (i)

wherein:

A' is a 5- or 6-membered aromatic or heteroaromatic ring containing 0 to 4 heteroatoms selected from the group consisting of N, O, and S;

r is an integer ranging from 1 to 20;

 R_4 is selected from the group consisting of H; NH_2 ; $(CH_2)_sOH$, wherein s is an integer ranging from 1 to 8; $R_{14}COOH$, wherein R_{14} is an alkyl or alkylidene group having 1 to 8 carbon atoms, halo, NHR_8 , NR_8R_9 , $NHCOR_8$, NR_8COR_9 , SO_3H and PO_3H_2 ;

R₃ is selected from the group consisting of H, NH₂, R₁₅COOH, wherein R₁₅ is an alkyl or alkylidene group having 1 to 8 carbon atoms, and (CH₂)_tOH, wherein t is an

integer ranging from 1 to 8; halo, NHR₈, NR₈R₉, NHCOR₈, NR₈COR₉, SO₃H and PO_3H_2 ;

q is an integer ranging from 1 to 8;

or R₁ is a C₁-C₈ alkanyl group, C₂-C₈-alkenyl- or C2-C8 -alkynyl- group which is optionally substituted by -CN, -CH₂NR₆R₇OH, -OR₈, -NR₆R₇, -NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH, -OCH₂COOR₈, -SO₂R₅, -S-R₅, -NHCONH phenyl, -OCH₂-CONR₆R₇, -OCH₂CH₂OH, -SO₂-CH₂-CH₂-O-COR₈, -OCH₂-CH₂-NR₆R₇, -SO₂-CH₂-CH₂-OH, -CONHSO₂R₈, -CH₂CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH, --COOR₈, -CONR₆R₇, -CHO, -SR₈, -SO₈, -SO₂R₈, -SO₃H, -PO₃H₂, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉, -CH(OR₈)₂, -CH=CH-R₁₀, -OCONR₆R₇,

$$H$$
 C
 N
 N
 R_{11}
 NH_2
 NH
 NH_2

or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted by methyl; or

denotes phenyl-C₁-C₆-alkylene, phenyl-C₂-C₆-alkenylene or phenyl-C₂-C₆-alkynylene, in which the phenyl ring is optionally substituted, either directly or via a C₁-C₄-alkylene group, with one or more of the following groups: -C₁-C₃-alkyl, -CN, -CH₂NR₆R₇, -NO₂, -OH, -OR₈, -CH₂-NH-SO₂-R₈, -NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅, -OCH₂-CONR₆R₇, -OCH₂-CH₂-NR₆R₇, -CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH, -COOR₈, -CF₃, cyclopropyl, -CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO, -SR₈, -SO₈, -SO₂R₈, -SO₃H, -PO₃H₂, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉, -CH(OR₈)₂, -NHCOOR₈, -CH₂CONHSO₂R₈, -CH=CH-R₁₀, -OCONR₆R₇, -CH₂-O-CONR₆R₇, -CH₂-C-CONR₆R₇,

i 1.

$$H \longrightarrow C \longrightarrow N \longrightarrow NH$$
 $NH_2 \longrightarrow NH$
 $NH_2 \longrightarrow NH$
 $NH_2 \longrightarrow NH$

or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted by methyl; or

denotes C₃-C₇-cycloalkyl-C₁-C₆-alkylene-, C₃-C₇-cycloalkyl-C₂-C₆-alkenylene-, C₃-C₇ -cycloalkyl-C₂-C₆-alkynylene-, in which the cycloalkyl group may optionally be substituted, either directly or via a C₁₋₄-alkylene group, by -CN, -CH₂NR₆R₇, =O, -OH, -OR₈, -NR₆R₇, -NHCOR₈, -NHCONR₆R₇, halogen, --OCOR₈, -OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅, -OCH₂CONR₆R₇, -OCH₂CH₂OH, -OCH₂-CH₂-NR₆R₇, -OCH₂CH₂OR₈, -COOH, -COOR₈, -CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO, -SR₈, -SO₂R₈, -SO₃H, -PO₃H₂, -SO₂NR₆R₇, -OCH₂-CH₂-OCOR₈, -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉, -CONHSO₂R₈, -CH(OR₈)₂, -NHCOOR₈, -CH=CH-R₁₀, -OCONR₆R₇, -CH₂-O-CONR₆R₇, -CH₂-O-CONR₆R₇,

or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted by methyl; or

denotes a group of the formula A-C₁-C₆-alkylene-, A-CONH-C₁-C₆-alkylene-, A-CONH-C₂-C₆-alkenylene-, A-CONH-C₂-C₆-alkynylene-, A-NH-CO-C₁-C₆-alkylene, A-NH-CO-C₂-C₆-alkenylene, A-NH-CO-C₂-C₆-alkynylene, A-C₂-C₆-alkenylene- or A-C₂-C₆-alkynylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring, 5- or 6-membered aromatic ring, or 5-or 6-membered heteroaromatic ring which contains

nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, by C₁-C₄-alkyl, halogen, --OR₈, -CN, --NO₂, -NH₂, -CH₂NR₆R₇, -OH, =O, a ketal, -COOH, -SO₃H, -PO₃H₂, -COOR₈, -CONR₆R₇, -COR₉, -SO₂-R₈, -CONR₆R₇ or



 R_5 denotes C_1 - C_4 -alkyl, optionally substituted by OH, OCOR₈, NH₂, NR₆R₇ or NHCOR₈,

 R_6 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, preferably a C_1 - C_4 -alkyl group, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , or it denotes --(CH_2)_m—NHCOOR₈ wherein m=1, 2, 3 or 4;

R₇ denotes hydrogen, an optionally substituted C₃₋₆-cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C₁ to C₈, -or it denotes --(CH₂)_m-NHCOOR₈ wherein m=1, 2, 3 or 4; or R₆ and R₇ together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, while the heterocyclic ring may be substituted by a branched or unbranched C₁₋₄-alkyl group, or may carry one of the following groups: --(CH₂)_n-NH₂, =O, a ketal - preferably -O-CH₂-CH₂-O-, -(CH₂)_n-NH-C₁-C₄-alkyl, -(CH₂)_n-N(C₁-C₈-alkyl), -(CH₂)_n-NHCOOR₈, (n=2, 3, 4,), halogen, -OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇, -OH, -COOH, -SO₃H, -PO₃H₂, -COOR₈, -CONR₆R₇, -SO₂R₈,

R₈ denotes hydrogen, C₁-C₈-alkyl or C₂-C₈-alkenyl or C₂-C₈-alkynyl optionally substituted with CO₂H, a benzyl- or phenyl- group, which is optionally mono- or polysubstituted by OCH₃;

 R_9 denotes C_1 - C_8 -alkyl or C_2 - C_8 -alkenyl or C_2 - C_8 -alkynyl optionally substituted with CO_2H , optionally substituted phenyl, optionally substituted benzyl, C_3 - C_6 -cycloalkyl, and

R₁₀ denotes -COOR₈, -CH₂OR₈, -CONR₆R₇, hydrogen, C₁-C₃-alkyl, optionally substituted phenyl, --CH₂NR₆R₇;

and pharmaceutically acceptable salts, hydrates and prodrugs thereof.

- 2. The compound of claim 1, wherein at least one of R₃ and R₄ is independently selected from the group consisting of SO₃H and PO₃H₂.
- 3. The compound of claim 1, wherein R_1 or R_2 is a C_1 - C_8 alkanyl group, C_2 - C_8 -alkenyl group or C_2 - C_8 alkynyl group which is optionally substituted by NR_6R_7 , -SO₃H, or -PO₃H₂.
 - 4. The compound of claim 1, wherein A is phenyl.
 - 5. The compound of claim 1, wherein A' is phenyl.
 - 6. The compound of claim 1, wherein:

 R_1 is a C_1 - C_8 alkanyl group, C_2 - C_8 -alkenyl group or C_2 - C_8 alkynyl group which is optionally substituted by NR_6R_7 or $-SO_3H$;

A is phenyl; and

A' is phenyl.

- 7. The compound of claim 6, wherein at least one of R₃ and R₄ is independently selected from the group consisting of SO₃H and PO₃H₂.
- 8. The compound of claim 1, wherein said compound is selected from the group consisting of:
 - 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine;

- 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(3-pyridyl)methyl]xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(4-thiazolyl)methyl]xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-(4-sulfonoxybenzyl)xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-methoxypropyl)xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-dimethylamino)propylxanthine;
- 3-[2-[4-(6-Aminohexanoyl)aminophenyl]ethyl]-8-benzyl-1-propylxanthine;
- 8-Benzyl-1-propyl-3-[4-(4-sulfonoxyphenyl)butyl]xanthine;
- 8-Benzyl-1-propyl-3-[2-(4-sulfonoxyphenyl)ethyl]xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-sulfonoxypropyl)xanthine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
- 9. The compound of claim 1, wherein said compound is selected from the group consisting of:
 - 8-Benzyl-1-propyl-3-[4-(4-sulfonoxyphenyl)butyl]xanthine;
 - 8-Benzyl-1-propyl-3-[2-(4-sulfonoxyphenyl)ethyl]xanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-sulfonoxypropyl)xanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-8-(4-fluorobenzyl)-1-propylxanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(thiophen-2-yl)methyl]xanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(1*H*-tetrazol-5-yl)methyl]xanthine;
 - $8\hbox{-}(2\hbox{-}Ace tamin obenzyl)\hbox{-}3\hbox{-}[2\hbox{-}(4\hbox{-}amin ophenyl)\hbox{ethyl}]\hbox{-}1\hbox{-}propyl xan thine;}\\$
 - $8\hbox{-}(2\hbox{-}Amin obenzyl)\hbox{-}3\hbox{-}(2\hbox{-}phenylethyl)\hbox{-}1\hbox{-}propylx anthine;}\\$
 - 8-Benzyl-3-[2-(3-carboxyphenyl)ethyl]-1-propylxanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(8-sulfonoxyoctyl)xanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(5-sulfonoxypentyl)xanthine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
- 10. The compound of claim 1, wherein said compound is selected from the group consisting of:
 - 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine;
 - 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(3-pyridyl)methyl]xanthine;

- 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-(4-sulfonoxybenzyl)xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-methoxypropyl)xanthine;
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(3-dimethylamino)propylxanthine;
- 3-[2-[4-(6-Aminohexanoyl)aminophenyl]ethyl]-8-benzyl-1-propylxanthine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
- 11. The compound of claim 1, wherein said compound is selected from the group consisting of:
- 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-(5-sulfonoxypentyl)xanthine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
- 12. A composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.